Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an…
Forest Ray PhD, — 
Articles by
First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex…
MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials…
Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among…
No More Patients Needed in GENESIS Trial of Motixafortide, Committee Says
An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell…
Sarclisa Triple Combo Conditionally Approved for NHS Use in England, Wales
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the…
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing…